COLORECTAL ADENOCARCINOMA
Clinical trials for COLORECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new COLORECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for COLORECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests whether a combination of three drugs—cisplatin, nivolumab, and temozolomide—can shrink tumors in people with advanced colorectal cancer that has not responded to at least two prior treatments. The cancer must be mismatch repair-proficient (MMR-proficient), meanin…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
Vitamin D3 boost: could a simple supplement slow advanced colon cancer?
Disease control OngoingThis study tests whether adding high-dose vitamin D3 to standard chemotherapy and a targeted drug (bevacizumab) can help people with metastatic colorectal cancer live longer without their disease getting worse. About 455 adults who have not had prior treatment for advanced cancer…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New combo therapy shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests whether combining two drugs, cabozantinib and nivolumab, can help control advanced colorectal cancer that has stopped responding to standard treatments. About 48 adults with a specific type of cancer (MSS) that has spread will receive the drug combination. The ma…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New cancer drug TST003 enters human trials – hope for advanced tumors
Disease control OngoingThis early-stage trial tests the safety of TST003, a new drug given by IV every 3 weeks, in about 111 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, check side effects, and see if the drug can shrink tumors or slow their growth. Partic…
Matched conditions: COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:01 UTC